

## Special Issue

# Neoadjuvant Chemotherapy in Pancreatic Cancer

### Message from the Guest Editor

Pancreatic cancer remains one of the most aggressive malignancies, with limited treatment options and poor overall survival rates. Neoadjuvant chemotherapy (NAC) has gained increasing attention as a strategy to improve surgical outcomes, enhance tumor resectability, and potentially increase long-term survival in patients with (borderline) resectable and locally advanced pancreatic cancer. However, careful patient selection is crucial to ensure that only those who will genuinely benefit from surgery proceed to resection, as not all patients respond favorably to NAC. Identifying reliable biomarkers and imaging criteria to predict response and optimize treatment decisions remains a key challenge. This Special Issue examines the evolving role of NAC in pancreatic cancer, focusing on treatment protocols, clinical outcomes, resistance mechanisms, patient selection, and emerging biomarkers. We invite original research, reviews, and clinical studies offering insights into optimizing NAC strategies and improving patient prognosis. The goal is to advance understanding and discuss integrating NAC into standard treatment and selecting surgical candidates post-NAC.

### Guest Editor

Prof. Dr. Casper H. J. Van Eijck

Department of Surgery, Erasmus MC, University Medical Center Rotterdam, 3000 CA Rotterdam, The Netherlands

### Deadline for manuscript submissions

31 December 2025



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/232899](https://mdpi.com/si/232899)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)